Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Ann Surg Oncol

Retrieve available abstracts of 118 articles:
HTML format



Single Articles


    December 2022
  1. TAKAMOCHI K, Tsuboi M, Okada M, Niho S, et al
    ASO Visual Abstract: S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial.
    Ann Surg Oncol. 2022;29:8209-8210.
    PubMed    


  2. TAKAMOCHI K, Tsuboi M, Okada M, Niho S, et al
    S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial.
    Ann Surg Oncol. 2022;29:8198-8206.
    PubMed     Abstract available


    November 2022
  3. USUZAKI T, Takahashi K, Ishikuro M, Obara T, et al
    Letter to the Editor: Comment on ''Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer''.
    Ann Surg Oncol. 2022 Nov 16. doi: 10.1245/s10434-022-12809.
    PubMed    


  4. SHIMADA Y
    Reply to: Letter to the Editor: Comment on ''Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer'' by Usuzaki, Takuma et al.
    Ann Surg Oncol. 2022 Nov 14. doi: 10.1245/s10434-022-12822.
    PubMed    


  5. COURELLI AS, Sharma AK, Madlensky L, Choi YY, et al
    ASO Visual Abstract: Co-localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series.
    Ann Surg Oncol. 2022;29:7551-7552.
    PubMed    


  6. CHEN LW, Yang SM, Chuang CC, Wang HJ, et al
    ASO Visual Abstract: Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography.
    Ann Surg Oncol. 2022;29:7483-7484.
    PubMed    


  7. COURELLI AS, Sharma AK, Sicklick JK
    ASO Author Reflections: Co-Localization of Synchronous Gastrointestinal Stromal Tumors (GISTs) and Peritoneal Mesothelioma (PM): A Case Series.
    Ann Surg Oncol. 2022;29:7549-7550.
    PubMed    


  8. COURELLI AS, Sharma AK, Madlensky L, Choi YY, et al
    Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series.
    Ann Surg Oncol. 2022;29:7542-7548.
    PubMed     Abstract available


  9. OLIVER AL, Takahashi-Pipkin C, Wong JH, Burch AE, et al
    Disparate Access to Surgery for Operable Carcinoma of the Lung in North Carolina.
    Ann Surg Oncol. 2022;29:7485-7493.
    PubMed     Abstract available


  10. CHEN LW, Yang SM, Chuang CC, Wang HJ, et al
    Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography.
    Ann Surg Oncol. 2022;29:7473-7482.
    PubMed     Abstract available


    October 2022
  11. HERREROS-POMARES A, Doria P, Gallach S, Meri-Abad M, et al
    ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients.
    Ann Surg Oncol. 2022 Oct 28. pii: 10.1245/s10434-022-12717.
    PubMed    


  12. LI D, Deng C, Fu F, Bai J, et al
    ASO Visual Abstract: Impact of Prior Cancer History on Outcomes of Resected Lung Cancer.
    Ann Surg Oncol. 2022 Oct 20. pii: 10.1245/s10434-022-12658.
    PubMed    


  13. BONNER SN, He C, Clark M, Adams K, et al
    ASO Visual Abstract: Understanding Racial Differences in Lung Cancer Surgery Through a Statewide Quality Collaborative.
    Ann Surg Oncol. 2022 Oct 16. pii: 10.1245/s10434-022-12546.
    PubMed    


  14. GOMBODORJ N, Azuma Y, Yokobori T, Erkhem-Ochir B, et al
    RAB11A Expression Is Associated With Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma.
    Ann Surg Oncol. 2022;29:7149-7162.
    PubMed     Abstract available


    September 2022
  15. SHIMADA Y, Kudo Y, Maehara S, Amemiya R, et al
    ASO Visual Abstract: Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer.
    Ann Surg Oncol. 2022 Sep 26. pii: 10.1245/s10434-022-12534.
    PubMed    


  16. HERREROS-POMARES A, Doria P, Gallach S, Meri-Abad M, et al
    A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients.
    Ann Surg Oncol. 2022 Sep 21. pii: 10.1245/s10434-022-12565.
    PubMed     Abstract available


  17. HERREROS-POMARES A, Jantus-Lewintre E
    ASO Author Reflections: Key Components of the Hedgehog Signaling Pathway as Prognostic Biomarkers in Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Sep 20. pii: 10.1245/s10434-022-12590.
    PubMed    


  18. SHIMADA Y
    ASO Author Reflections: The Clinical Use of Radiomics with Artificial Intelligence in Patients with Early-Stage Lung Cancer.
    Ann Surg Oncol. 2022 Sep 13. pii: 10.1245/s10434-022-12518.
    PubMed    


  19. WANG Z, Yang Z, Li S, Zhang J, et al
    ASO Visual Abstract: A Comprehensive Comparison of Different Nodal Subclassification Methods in Surgical Resected Non-Small Cell Lung Cancer Patients.
    Ann Surg Oncol. 2022 Sep 9. pii: 10.1245/s10434-022-12413.
    PubMed    


  20. TEKE ME, Saif A, Sarvestani AL, Hernandez JM, et al
    A Phase III, Randomized, Controlled Trial Comparing Open Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
    Ann Surg Oncol. 2022 Sep 9. pii: 10.1245/s10434-022-12488.
    PubMed    


  21. SHIMADA Y, Kudo Y, Maehara S, Amemiya R, et al
    Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer.
    Ann Surg Oncol. 2022 Sep 7. pii: 10.1245/s10434-022-12516.
    PubMed     Abstract available


  22. WANG Y, Chen Y, Yang Z, Qian F, et al
    Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Ann Surg Oncol. 2022;29:5666-5678.
    PubMed     Abstract available


  23. WANG Y, Han B
    ASO Author Reflections: Pure and Combined Surgically Resected Large Cell Neuroendocrine Carcinoma of Lung: Could They be Evaluated as a Single Entity?
    Ann Surg Oncol. 2022;29:5679-5680.
    PubMed    


  24. KAWAKATSU S, Shimizu Y, Natsume S, Okuno M, et al
    Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systematic Review of the Literature.
    Ann Surg Oncol. 2022;29:5972-5983.
    PubMed     Abstract available


  25. XU W, Dai W, Gao Z, Wang XS, et al
    Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery.
    Ann Surg Oncol. 2022;29:5593-5604.
    PubMed     Abstract available


    August 2022
  26. BONNER SN, He C, Clark M, Adams K, et al
    Understanding Racial Differences in Lung Cancer Surgery Through a Statewide Quality Collaborative.
    Ann Surg Oncol. 2022 Aug 26. pii: 10.1245/s10434-022-12435.
    PubMed     Abstract available


  27. YANG Z, Wang Z, Liu L
    ASO Author Reflections: Comprehensive Comparison of N Staging Subclassification Methods for Non-Small-Cell Lung Cancer.
    Ann Surg Oncol. 2022 Aug 21. pii: 10.1245/s10434-022-12398.
    PubMed    


  28. WANG Z, Yang Z, Li S, Zhang J, et al
    A Comprehensive Comparison of Different Nodal Subclassification Methods in Surgically Resected Non-Small-Cell Lung Cancer Patients.
    Ann Surg Oncol. 2022 Aug 18. pii: 10.1245/s10434-022-12363.
    PubMed     Abstract available


  29. CHENG X, Zeng W, Liu Y, Song Z, et al
    ASO Visual Abstract: Impact of Lymph Node Dissection on Survival and Tumor Recurrence in Patients with Resected cT1-2N0 Small-Cell Lung Cancer.
    Ann Surg Oncol. 2022 Aug 13. pii: 10.1245/s10434-022-12283.
    PubMed    


  30. SORAN A, Ozbas S, Ozcinar B, Isik A, et al
    ASO Visual Abstract: Intervention for Hepatic and Pulmonary METastases in Breast Cancer Patients-Prospective, Multi-Institutional Registry Study: IMET; Protocol MF 14-02.
    Ann Surg Oncol. 2022 Aug 6. pii: 10.1245/s10434-022-12320.
    PubMed    


  31. KLEMEN ND, Court CM, Fernandes MC, Walch HS, et al
    Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade.
    Ann Surg Oncol. 2022 Aug 5. pii: 10.1245/s10434-022-12095.
    PubMed     Abstract available


    July 2022
  32. CHENG X, Zeng W, Liu Y, Song Z, et al
    Impact of Lymph Node Dissection on Survival and Tumor Recurrence for Patients with Resected cT1-2N0 Small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Jul 29. pii: 10.1245/s10434-022-12215.
    PubMed     Abstract available


  33. SORAN A, Ozbas S, Ozcinar B, Isik A, et al
    Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study-IMET, Protocol MF 14-02.
    Ann Surg Oncol. 2022 Jul 25. pii: 10.1245/s10434-022-12239.
    PubMed     Abstract available


  34. BURCH AE, Wong JH, Irish WD
    ASO Author Reflections: Identifying and Understanding Disparities in Access to Surgery: Operable Lung Cancer in North Carolina.
    Ann Surg Oncol. 2022 Jul 12. pii: 10.1245/s10434-022-12179.
    PubMed    


    June 2022
  35. USHITANI Y, Shimada Y, Yamada Y, Kudo Y, et al
    ASO Visual Abstract: Clinical Impact of Sarcopenia 1 Year after Surgery in Patients with Early-Stage Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Jun 28. pii: 10.1245/s10434-022-12068.
    PubMed    


  36. USHITANI Y, Shimada Y, Yamada Y, Kudo Y, et al
    Clinical Impact of Sarcopenia 1 Year After Surgery for Patients with Early-Stage Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Jun 21. pii: 10.1245/s10434-022-11999.
    PubMed     Abstract available


  37. MATSUGUMA H, Mun M, Sano A, Yoshino I, et al
    Time to Incurable Recurrence for Patients Treated With Pulmonary Metastasectomy for Colorectal Cancer.
    Ann Surg Oncol. 2022 Jun 18. pii: 10.1245/s10434-022-11904.
    PubMed     Abstract available


  38. USHITANI Y, Shimada Y
    ASO Author Reflections: Management to Prevent Postoperative Sarcopenia in Patients with Lung Cancer.
    Ann Surg Oncol. 2022 Jun 14. pii: 10.1245/s10434-022-12026.
    PubMed    


  39. BAILEY J, Van Haren RM
    Complementary Roles of Screening and Nodule Programs for Early Detection of Lung Cancer in Diverse Populations.
    Ann Surg Oncol. 2022 Jun 12. pii: 10.1245/s10434-022-11943.
    PubMed    


  40. IWASAKI M, Ishihara S, Okada S, Shimegi R, et al
    ASO Visual Abstract: Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Jun 3. pii: 10.1245/s10434-022-11907.
    PubMed    


  41. IWASAKI M, Ishihara S, Okada S, Shimegi R, et al
    Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Jun 2. pii: 10.1245/s10434-022-11835.
    PubMed     Abstract available


    May 2022
  42. DONINGTON JS
    Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care.
    Ann Surg Oncol. 2022 May 27. pii: 10.1245/s10434-022-11915.
    PubMed    


  43. IWASAKI M, Ishihara S, Inoue M
    ASO Author Reflections: Clinical Significance of Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2022 May 25. pii: 10.1245/s10434-022-11886.
    PubMed    


  44. KUO SW, Chen PH, Lu TP, Chen KC, et al
    ASO Visual Abstract: Primary Tumor Resection for Stage IV Non-Small-Cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.
    Ann Surg Oncol. 2022 May 15. pii: 10.1245/s10434-022-11687.
    PubMed    


  45. KHAN TM, Verbus EA, Gandhi S, Heymach JV, et al
    Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR).
    Ann Surg Oncol. 2022 May 9. pii: 10.1245/s10434-022-11627.
    PubMed    


  46. TEKE ME, Sarvestani AL, Hernandez JM, Fernando HC, et al
    A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).
    Ann Surg Oncol. 2022 May 6. pii: 10.1245/s10434-022-11584.
    PubMed    


  47. DONINGTON JS
    The Increasing Role of Surgery in Comprehensive Treatment of Advanced Non-small Cell Lung Cancer with Targetable Mutations.
    Ann Surg Oncol. 2022 May 6. pii: 10.1245/s10434-022-11764.
    PubMed    


  48. DHANASOPON AP, Boffa DJ
    Defining Relevancy in Patient-Reported Outcomes for Lung Cancer Surgery.
    Ann Surg Oncol. 2022 May 3. pii: 10.1245/s10434-022-11797.
    PubMed    


  49. YUN JK, Kim YH
    ASO Author Reflections: Could VAMLA be a Therapeutic Strategy in Selected Patients with Left-sided NSCLC?
    Ann Surg Oncol. 2022;29:2840-2841.
    PubMed    


    April 2022
  50. KUO SW, Chen PH, Lu TP, Chen KC, et al
    Correction to: Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.
    Ann Surg Oncol. 2022 Apr 9. pii: 10.1245/s10434-022-11714.
    PubMed    


  51. CUI C, Lian B, Zhang X, Wu D, et al
    An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.
    Ann Surg Oncol. 2022 Apr 9. pii: 10.1245/s10434-022-11670.
    PubMed     Abstract available


    March 2022
  52. CHEN PH, Kuo SW, Chen JS
    ASO Author Reflection: Primary Tumor Resection for Stage IV Lung Cancer after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
    Ann Surg Oncol. 2022 Mar 21. pii: 10.1245/s10434-022-11487.
    PubMed    


  53. KUO SW, Chen PH, Lu TP, Chen KC, et al
    Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.
    Ann Surg Oncol. 2022 Mar 7. pii: 10.1245/s10434-022-11483.
    PubMed     Abstract available


  54. KEPENEKIAN V, Peron J, You B, Bonnefoy I, et al
    Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.
    Ann Surg Oncol. 2022;29:2104-2113.
    PubMed     Abstract available


  55. KEPENEKIAN V, Peron J, You B, Glehen O, et al
    ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection.
    Ann Surg Oncol. 2022;29:2114-2115.
    PubMed    


    February 2022
  56. WANKHEDE D, Grover S
    ASO Visual Abstract: Outcomes Following Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-Analysis.
    Ann Surg Oncol. 2022 Feb 21. pii: 10.1245/s10434-022-11391.
    PubMed    


  57. WANG ZN, Jiang XB, Lu J, Guo XY, et al
    Survival Benefit from Surgical Resection in Lung Cancer Patients with Brain Metastases: a Single-Center, Propensity-Matched Analysis Cohort Study.
    Ann Surg Oncol. 2022 Feb 18. pii: 10.1245/s10434-022-11365.
    PubMed     Abstract available


  58. LIU C, Wang W, Mei J, Zhu Y, et al
    Uniportal Thoracoscopic Single-Direction Basal Subsegmentectomy (Left S10a+ci): Trans-Inferior-Pulmonary-Ligament Approach.
    Ann Surg Oncol. 2022;29:1389-1391.
    PubMed     Abstract available


    January 2022
  59. KRUMEICH LN, Roses RE, Kuo LE, Lindeman BM, et al
    ASO Visual Abstract: Survival After Adrenalectomy for Metastatic Lung Cancer.
    Ann Surg Oncol. 2022 Jan 29. pii: 10.1245/s10434-021-11282.
    PubMed    


  60. YUN JK, Yoo S, Lee GD, Choi S, et al
    Comparison of Long-Term Outcomes Between Minimally Invasive Pulmonary Resection With and Without Video-Assisted Mediastinoscopic Lymphadenectomy for Left-Sided Lung Cancer.
    Ann Surg Oncol. 2022 Jan 13. pii: 10.1245/s10434-021-11191.
    PubMed     Abstract available


  61. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients With Non-Small Cell Lung Cancer.
    Ann Surg Oncol. 2022 Jan 8. pii: 10.1245/s10434-021-11024.
    PubMed     Abstract available


  62. LEECH MM, Weiss JE, Markey C, Loehrer AP, et al
    Influence of Race, Insurance, Rurality, and Socioeconomic Status on Equity of Lung and Colorectal Cancer Care.
    Ann Surg Oncol. 2022 Jan 7. pii: 10.1245/s10434-021-11160.
    PubMed     Abstract available


  63. KRUMEICH LN, Roses RE, Kuo LE, Lindeman BM, et al
    Survival After Adrenalectomy for Metastatic Lung Cancer.
    Ann Surg Oncol. 2022 Jan 6. pii: 10.1245/s10434-021-11192.
    PubMed     Abstract available


  64. KARUSH JM
    Segmentectomy...Because We Can or Because We Should?
    Ann Surg Oncol. 2022;29:28-29.
    PubMed    


  65. DAI W, Mu Y, Chang S, Wu Z, et al
    ASO Author Reflections: Using Patient-Reported Outcomes to Compare Thoracoscopic Segmentectomy and Lobectomy.
    Ann Surg Oncol. 2022;29:557-558.
    PubMed    


  66. LI Z, He W, Wang C
    ASO Author Reflections: A Simple Method to Predict Risk Factors of Complications After Pneumonectomy.
    Ann Surg Oncol. 2022;29:570-571.
    PubMed    


    December 2021
  67. HANDA Y, Tsutani Y, Okada M
    ASO Author Reflection: Position of the Complex Segmentectomy on Postoperative Pulmonary Function.
    Ann Surg Oncol. 2021;28:8356-8357.
    PubMed    


  68. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Postoperative Pulmonary Function After Complex Segmentectomy.
    Ann Surg Oncol. 2021;28:8347-8355.
    PubMed     Abstract available


  69. CHIANG XH, Lu TP, Hsieh MS, Tsai TM, et al
    Thoracoscopic Wedge Resection Versus Segmentectomy for cT1N0 Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:8398-8411.
    PubMed     Abstract available


  70. LEE G, Yoon S, Ahn B, Kim HR, et al
    ASO Visual Abstract: Blood Vessel Invasion Predicts Postoperative Survival Outcomes and Systemic Recurrence Regardless of Location or Blood Vessel Type in Patients with Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28.
    PubMed    


  71. CHIANG XH, Lu TP, Hsieh MS, Tsai TM, et al
    ASO Visual Abstract: Thoracoscopic Wedge Resection Versus Segmentectomy for cT1N0 Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28.
    PubMed    


  72. ZHAO ZR, Liu DH, Wang YZ, Sun XS, et al
    ASO Visual Abstract: Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma.
    Ann Surg Oncol. 2021;28.
    PubMed    


  73. SHIGEFUKU S
    Reply to "Ground Glass Opacity (GGO) Predicts Improved Survival of Pathologic Stage I Lung Adenocarcinoma Patients" by Guowei Che et al.
    Ann Surg Oncol. 2021;28.
    PubMed    


  74. WANG Y, Che G
    Ground Glass Opacity (GGO) Predicts Improved Survival of Pathologic Stage I Lung Adenocarcinoma Patients.
    Ann Surg Oncol. 2021;28.
    PubMed    


    November 2021
  75. SUN C, Anraku M, Nakajima J
    ASO Author Reflections: An Evolving Skeletal Muscle Profiling-Towards Precise Host Phenotype and Prognostic Stratification in Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2021 Nov 20. pii: 10.1245/s10434-021-11025.
    PubMed    


  76. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    ASO Visual Abstract: Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients with Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2021 Nov 20. pii: 10.1245/s10434-021-11071.
    PubMed    


  77. VAN JOOLINGEN WH, Rasing MJA, Peters M, van Lindert ASR, et al
    ASO Visual Abstract: Non-small Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection-can Chemoradiotherapy Offer Similar Survival?
    Ann Surg Oncol. 2021 Nov 20. pii: 10.1245/s10434-021-11061.
    PubMed    


  78. JOHANSON H, Okereke I
    The Importance of Clinical Decision-Making in Surgical Planning for Non-Small Cell Lung Cancer.
    Ann Surg Oncol. 2021 Nov 8. pii: 10.1245/s10434-021-11027.
    PubMed    


  79. DAI W, Chang S, Pompili C, Qiu B, et al
    Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer.
    Ann Surg Oncol. 2021 Nov 6. pii: 10.1245/s10434-021-10946.
    PubMed     Abstract available


  80. LEE G, Yoon S, Ahn B, Kim HR, et al
    Blood Vessel Invasion Predicts Postoperative Survival Outcomes and Systemic Recurrence Regardless of Location or Blood Vessel Type in Patients with Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:7279-7290.
    PubMed     Abstract available


    October 2021
  81. VAN JOOLINGEN WH, Rasing MJA, Peters M, van Lindert ASR, et al
    Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival?
    Ann Surg Oncol. 2021 Oct 30. pii: 10.1245/s10434-021-10982.
    PubMed     Abstract available


  82. DAI W, Chang S, Pompili C, Qiu B, et al
    ASO Visual Abstract: Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2021 Oct 23. pii: 10.1245/s10434-021-10963.
    PubMed    


  83. HANDA Y, Tsutani Y, Okada M
    Reply to "Lobe-Specific Lymph Node Dissection for Lung Cancer: Is It Still Feasible?" by Han-Yu Deng.
    Ann Surg Oncol. 2021 Oct 9. pii: 10.1245/s10434-021-10684.
    PubMed    


  84. SHI Y, Wu S, Ma S, Lyu Y, et al
    Comparison Between Wedge Resection and Lobectomy/Segmentectomy for Early-Stage Non-small Cell Lung Cancer: A Bayesian Meta-analysis and Systematic Review.
    Ann Surg Oncol. 2021 Oct 6. pii: 10.1245/s10434-021-10857.
    PubMed     Abstract available


  85. ZHU Y, Xia L, Liu C, Lin F, et al
    Uniportal Single-Direction Thoracoscopic Right S9 Segmentectomy: Trans-Inferior-Pulmonary-Ligament Approach.
    Ann Surg Oncol. 2021;28:6407.
    PubMed     Abstract available


  86. NISHINO T, Toba H, Yoshida T, Inoue S, et al
    Endobronchial Ultrasound Improves the Diagnosis of the Tracheobronchial Invasion of Advanced Esophageal Cancer.
    Ann Surg Oncol. 2021;28:6398-6406.
    PubMed     Abstract available


  87. LEPPELMANN KS, Levesque VM, Bunck AC, Cahalane AM, et al
    Outcomes Following Percutaneous Microwave and Cryoablation of Lung Metastases from Adenoid Cystic Carcinoma of the Head and Neck: A Bi-Institutional Retrospective Cohort Study.
    Ann Surg Oncol. 2021;28:5829-5839.
    PubMed     Abstract available


  88. LI S, Qiao S, Li N, Zhu X, et al
    MiR-744 Functions as an Oncogene Through Direct Binding to c-Fos Promoter and Facilitates Non-small Cell Lung Cancer Progression.
    Ann Surg Oncol. 2021 Oct 1. pii: 10.1245/s10434-021-10688.
    PubMed     Abstract available


  89. LEPPELMANN KS, Fintelmann FJ
    ASO Author Reflections: Percutaneous Image-Guided Ablation and Multi-modality Management of Lung Metastases.
    Ann Surg Oncol. 2021;28:5840-5841.
    PubMed    


    September 2021
  90. WEI X, Yu H, Dai W, Mu Y, et al
    Correction to: Patient-Reported Outcomes of Video-Assisted Thoracoscopic Surgery Versus Thoracotomy for Locally Advanced Lung Cancer: A Longitudinal Cohort Study.
    Ann Surg Oncol. 2021 Sep 24. pii: 10.1245/s10434-021-10798.
    PubMed    


  91. HANDA Y, Tsutani Y, Okada M
    ASO Author Reflections: Survival Outcomes between Patients with Hypermetabolic Non-small Cell Lung Cancer Undergoing Systematic and Lobe-Specific Mediastinal Lymph Node Dissection.
    Ann Surg Oncol. 2021 Sep 3. pii: 10.1245/s10434-021-10037.
    PubMed    


    August 2021
  92. DENG HY
    Lobe-Specific Lymph Node Dissection for Lung Cancer: Is it Still Feasible?
    Ann Surg Oncol. 2021 Aug 21. pii: 10.1245/s10434-021-10671.
    PubMed    


  93. WANG C, Wang S, Li Z, He W, et al
    ASO Visual Abstract: A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-small Cell Lung Cancer Patients.
    Ann Surg Oncol. 2021 Aug 3. pii: 10.1245/s10434-021-10542.
    PubMed    


  94. ZHAO ZR, Liu DH, Wang YZ, Sun XS, et al
    Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma.
    Ann Surg Oncol. 2021;28:4542-4550.
    PubMed     Abstract available


  95. ZHAO ZR, Long H
    ASO Author Reflections: Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma.
    Ann Surg Oncol. 2021;28:4551-4552.
    PubMed    


    July 2021
  96. WANG C, Wang S, Li Z, He W, et al
    A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients.
    Ann Surg Oncol. 2021 Jul 28. pii: 10.1245/s10434-021-10504.
    PubMed     Abstract available


  97. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Systematic Versus Lobe-Specific Mediastinal Lymphadenectomy for Hypermetabolic Lung Cancer.
    Ann Surg Oncol. 2021 Jul 3. pii: 10.1245/s10434-021-10020.
    PubMed     Abstract available


  98. FU X, Wang F, Su X, Luo G, et al
    Endobronchial Ultrasound Improves Evaluation of Recurrent Laryngeal Nerve Lymph Nodes in Esophageal Squamous Cell Carcinoma Patients.
    Ann Surg Oncol. 2021;28:3930-3938.
    PubMed     Abstract available


  99. KIM IA, Hur JY, Kim HJ, Park JH, et al
    Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:3983-3993.
    PubMed     Abstract available


  100. KIM IA, Kim WS, Lee KY
    ASO Author Reflections: CTNNB1 and Fusion Genes as Predictors for Recurrence in Resected Early-Stage Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:3994-3995.
    PubMed    


    June 2021
  101. CHIANG XH, Lin MW, Hsu HH, Chen JS, et al
    ASO Author Reflection: Comparing Wedge Resection and Segmentectomy as the Appropriate Surgical Method in cT1N0 Lung Cancer.
    Ann Surg Oncol. 2021 Jun 5. pii: 10.1245/s10434-021-10214.
    PubMed    


  102. NAKAMURA A, Kondo N, Nakamichi T, Hashimoto M, et al
    Complications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
    Ann Surg Oncol. 2021;28:3057-3065.
    PubMed     Abstract available


  103. MATSUBARA T, Okamoto T
    ASO Author Reflections: The C-Reactive Protein (CRP)-Albumin Ratio May Be Useful as the Most Prognostic Index Among the Immuno-nutritional Parameters Using CRP and Albumin for Resected NSCLC.
    Ann Surg Oncol. 2021;28:3055-3056.
    PubMed    


    May 2021
  104. WEI X, Yu H, Shi Q
    ASO Author Reflections: Using Patient-Reported Outcomes to Evaluate Surgical Approaches for Locally Advanced Lung Cancer.
    Ann Surg Oncol. 2021 May 15. pii: 10.1245/s10434-021-10018.
    PubMed    


  105. LOTZE MT, Dhupar R
    ASO Author Reflection: Viruses, the Lung, and Thoracic Neoplasms: Breaking Bad.
    Ann Surg Oncol. 2021;28:2728-2729.
    PubMed    


    April 2021
  106. MIMAE T, Saji H, Nakamura H, Okumura N, et al
    Survival of Octogenarians with Early-Stage Non-small Cell Lung Cancer is Comparable Between Wedge Resection and Lobectomy/Segmentectomy: JACS1303.
    Ann Surg Oncol. 2021 Apr 26. pii: 10.1245/s10434-021-09835.
    PubMed     Abstract available


  107. WEI X, Yu H, Dai W, Mu Y, et al
    Patient-Reported Outcomes of Video-Assisted Thoracoscopic Surgery Versus Thoracotomy for Locally Advanced Lung Cancer: A Longitudinal Cohort Study.
    Ann Surg Oncol. 2021 Apr 20. pii: 10.1245/s10434-021-09981.
    PubMed     Abstract available


  108. GOOSEMAN MR, Brunelli A
    Intraoperative Lymph Node Management During Non-small Cell Lung Cancer Surgery.
    Ann Surg Oncol. 2021 Apr 16. pii: 10.1245/s10434-021-10039.
    PubMed    


  109. KANTOR T, Wakeam E
    Landmark Trials in the Surgical Management of Mesothelioma.
    Ann Surg Oncol. 2021;28:2037-2047.
    PubMed     Abstract available


  110. CHEN D, Ding Q, Wang W, Wang X, et al
    Characterization of Extracapsular Lymph Node Involvement and Its Clinicopathological Characteristics in Stage II-IIIA Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:2088-2098.
    PubMed     Abstract available


  111. KAGIMOTO A, Tsutani Y, Okada M
    ASO Author Reflections: Usefulness of Visual Evaluation of PET in Predicting Prognosis after Lung Resection for Early-Stage Lung Adenocarcinoma and Selecting Candidates for Sublobar Resection.
    Ann Surg Oncol. 2021;28:2076-2077.
    PubMed    


  112. KAGIMOTO A, Tsutani Y, Handa Y, Mimae T, et al
    Patient Selection of Sublobar Resection Using Visual Evaluation of Positron-Emission Tomography (PET) for Early-Stage Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:2068-2075.
    PubMed     Abstract available


    February 2021
  113. BATCHELOR T, Hasan J, Macbeth F, Shackcloth M, et al
    Randomised Controlled Trial Evidence Questions the Assumption that Pulmonary Metastasectomy Benefits Patients with Colorectal Cancer.
    Ann Surg Oncol. 2021 Feb 15. pii: 10.1245/s10434-020-09521.
    PubMed     Abstract available


  114. VAN VEENENDAAL LM, Bertolli E, Korse CM, Klop WMC, et al
    The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC).
    Ann Surg Oncol. 2021;28:1019-1028.
    PubMed     Abstract available


    January 2021
  115. SHIGEFUKU S, Shimada Y
    ASO Author Reflections: Impact of Ground-Glass Opacity Components in Long-Term Survivors with Resected Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:157-158.
    PubMed    


  116. OHTSUKA T
    Importance of Ground-Glass Opacity in Long-Term Survivors of Lung Adenocarcinoma: A Leopard Cannot Change Its Spots.
    Ann Surg Oncol. 2021;28:14-15.
    PubMed    


    October 2020
  117. DEMMY TL
    The Musician, Instrument, or Orchestra?
    Ann Surg Oncol. 2020;27:4088-4090.
    PubMed    


  118. JUNG W, Cho S
    ASO Author Reflections: Understanding Subsolid Lung Adenocarcinoma with Cystic Airspaces (LACA).
    Ann Surg Oncol. 2020;27:4404.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: